175 related articles for article (PubMed ID: 31986520)
1. Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?
James MH; Fragale JE; Aurora RN; Cooperman NA; Langleben DD; Aston-Jones G
Neuropsychopharmacology; 2020 Apr; 45(5):717-719. PubMed ID: 31986520
[No Abstract] [Full Text] [Related]
2. Suvorexant to treat alcohol use disorder and comorbid insomnia: Plan for a phase II trial.
Campbell EJ; Norman A; Bonomo Y; Lawrence AJ
Brain Res; 2020 Feb; 1728():146597. PubMed ID: 31837287
[TBL] [Abstract][Full Text] [Related]
3. A sleeping giant: Suvorexant for the treatment of alcohol use disorder?
Campbell EJ; Marchant NJ; Lawrence AJ
Brain Res; 2020 Mar; 1731():145902. PubMed ID: 30081035
[TBL] [Abstract][Full Text] [Related]
4. Suvorexant: first global approval.
Yang LP
Drugs; 2014 Oct; 74(15):1817-22. PubMed ID: 25227290
[TBL] [Abstract][Full Text] [Related]
5. [Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia].
Tanaka Y; Aoki I; Ishine T; Renger JJ; Winrow CJ; Hisada S
Nihon Yakurigaku Zasshi; 2016 Jul; 148(1):46-56. PubMed ID: 27430679
[No Abstract] [Full Text] [Related]
6. Chronopathophysiological implications of orexin in sleep disturbances and lifestyle-related disorders.
Tsuneki H; Wada T; Sasaoka T
Pharmacol Ther; 2018 Jun; 186():25-44. PubMed ID: 29289556
[TBL] [Abstract][Full Text] [Related]
7. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
Owen RT
Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
[TBL] [Abstract][Full Text] [Related]
8. Suvorexant (Belsomra) for insomnia.
Med Lett Drugs Ther; 2015 Mar; 57(1463):29-31. PubMed ID: 25719996
[No Abstract] [Full Text] [Related]
9. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.
Herring WJ; Roth T; Krystal AD; Michelson D
J Sleep Res; 2019 Apr; 28(2):e12782. PubMed ID: 30338596
[TBL] [Abstract][Full Text] [Related]
10. Preliminary examination of the orexin system on relapse-related factors in cocaine use disorder.
Suchting R; Yoon JH; Miguel GGS; Green CE; Weaver MF; Vincent JN; Fries GR; Schmitz JM; Lane SD
Brain Res; 2020 Mar; 1731():146359. PubMed ID: 31374218
[TBL] [Abstract][Full Text] [Related]
11. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
[TBL] [Abstract][Full Text] [Related]
12. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.
Sun H; Palcza J; Rosenberg R; Kryger M; Siringhaus T; Rowe J; Lines C; Wagner JA; Troyer MD
Respir Med; 2015 Mar; 109(3):416-26. PubMed ID: 25661282
[TBL] [Abstract][Full Text] [Related]
13. A new class of sedative/hypnotics: dual orexin receptor antagonists.
Simonson W
Geriatr Nurs; 2014; 35(6):462-3. PubMed ID: 25457290
[No Abstract] [Full Text] [Related]
14. New insights on the potential effect of orexin receptor antagonist suvorexant on Parkinson's disease symptoms.
Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; Saad HM; Batiha GE
Neurol Sci; 2024 May; 45(5):2367-2368. PubMed ID: 38231375
[No Abstract] [Full Text] [Related]
15. Benefits of switching to suvorexant for mild primary insomnia when sleepwalking episodes occur during zolpidem treatment.
Suzuki H; Hibino H; Inoue Y; Mikami A; Matsumoto H; Mikami K
Asian J Psychiatr; 2017 Dec; 30():122-123. PubMed ID: 28898806
[No Abstract] [Full Text] [Related]
16. Suvorexant for the Treatment of Insomnia in Adolescents.
Kawabe K; Horiuchi F; Ochi M; Nishimoto K; Ueno SI; Oka Y
J Child Adolesc Psychopharmacol; 2017 Nov; 27(9):792-795. PubMed ID: 28520464
[TBL] [Abstract][Full Text] [Related]
17. Effects of an orexin receptor antagonist on blood pressure and metabolic parameters.
Moriyama S; Yanai H; Takeuchi Y; Hayakawa T
J Clin Hypertens (Greenwich); 2018 May; 20(5):978-980. PubMed ID: 29700927
[No Abstract] [Full Text] [Related]
18. Benefits associated with switching from benzodiazepine hypnotics to suvorexant in patients with mild primary insomnia.
Suzuki H; Hibino H; Inoue Y; Mikami A; Matsumoto H; Mikami K
Asian J Psychiatr; 2017 Oct; 29():71-72. PubMed ID: 29061431
[No Abstract] [Full Text] [Related]
19. Timed Inhibition of Orexin System by Suvorexant Improved Sleep and Glucose Metabolism in Type 2 Diabetic db/db Mice.
Tsuneki H; Kon K; Ito H; Yamazaki M; Takahara S; Toyooka N; Ishii Y; Sasahara M; Wada T; Yanagisawa M; Sakurai T; Sasaoka T
Endocrinology; 2016 Nov; 157(11):4146-4157. PubMed ID: 27631554
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of suvorexant.
Stahl SM
CNS Spectr; 2016 Jun; 21(3):215-8. PubMed ID: 27322687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
